We highlight the significant impact of the CYP3A5 rs776746 polymorphism on the pharmacokinetics of TAC, such as TAC levels, C/D ratio or therapeutic index, and on clinical outcomes, such as AKI and GVHD. This evidence concerns the gene CYP3A5 and graft versus host disease.